The tar­get is the sys­tem: Con­den­sates biotech as­pires to ‘rewrite the rule­book’ on drug dis­cov­ery

An­oth­er biotech has burst in­to the buzzy but still bud­ding field of bio­mol­e­c­u­lar con­den­sates with $50 mil­lion in Se­ries A fund­ing.

Tran­si­tion Bio, based in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER